Connect to other sites within the UBM Medica Network
Pioglitazone Shows No Significant Association With Bladder Cancer Risk
Use of the diabetes drug pioglitazone was not associated with a significantly increased risk of bladder cancer, in a large cohort study.
Lymphoepithelioma-Like Carcinoma of the Urinary Bladder
A 65-year-old woman presented to a local emergency department complaining of right flank pain that had worsened over the past 10 days. A CT scan of the abdomen and pelvis showed intravesical tumors of the urinary bladder.
Heat Shock Protein Inhibitor May Benefit Bladder Cancer Patients
Advanced bladder cancer patients with poor prognosis appear to benefit from adding apatorsen 600 mg to first-line chemotherapy with gemcitabine/cisplatin.
Pembrolizumab Shows Antitumor Activity in Advanced Urothelial Cancer
Pembrolizumab demonstrates durable antitumor activity in patients with advanced urothelial cancer, with a higher response rate seen in patients with PD-L1 expression.
UTI Delayed Bladder Cancer Diagnosis in Medicare Population
Presentation with a urinary tract infection delayed a bladder cancer diagnosis among a population of Medicare patients, with worse delays experienced by women.
Pazopanib/Paclitaxel Combo Active in Refractory, Relapsed Urothelial Carcinoma
Phase II study results found that half of patients with relapsed or refractory urothelial carcinoma responded to treatment with pazopanib and paclitaxel.
New Era of Bladder Cancer Treatments Has Begun
In this interview we discuss the changing landscape of systemic therapies for the treatment of bladder cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.